AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03816280 — intervention group
Intervention type: PROCEDURE
Intervention: Alpha-stat acid-base management
Description: Acid-base status during CPB will be maintained using the alpha-stat regime
Study NCT00979862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT00979862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Given IV
Study NCT00979862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00838968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon-alpha
Description: interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
Study NCT04016727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
Study NCT01086267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-908662
Description: Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
Study NCT01086267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-908662
Description: Capsules, Oral, (TBD) mg, Q 12 h, Continuously
Study NCT01086267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
Study NCT04450862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural therapy self help intervention for anxiety
Description: The intervention will involve five key components:~Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease.~Cognitions - Identify and challenge negative automatic thoughts associated with anxiety.~Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH.~Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure.~Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving.
Study NCT03816280 — intervention group
Intervention type: PROCEDURE
Intervention: pH-stat acid-base management
Description: Acid-base status during CPB will be maintained using the pH-stat regime
Study NCT02022098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
Study NCT02022098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
Study NCT04187586 — intervention group
Intervention type: OTHER
Intervention: Extracorporeal shock wave therapy
Description: ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
Study NCT00425191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Gemcitabine
Description: Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
Study NCT00425191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Gemcitabine
Description: Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
Study NCT00425191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine cisplatin followed by docetaxel
Description: Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
Study NCT01969227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subanesthetic ketamine
Description: Ketamine drip at a subanesthetic infusion rate (low dose ketamine 5 - 10 mcg/kg/min)
Study NCT00554424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lignocaine
Description: 20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
Study NCT00554424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
Study NCT01060150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS Methylphenidate HCl
Description: Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
Study NCT03884049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: transcatheter arterial embolization of neovessels around the knee
Study NCT03884049 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham embolization
Description: Sham transcatheter arterial embolization of neovessels in the knee
Study NCT03138798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laboraide TM dental support device
Description: Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
Study NCT00728572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Logan Basic Technique and Surface EMG
Description: Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
Study NCT00728572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface EMG
Description: Surface EMG only, no intervention
Study NCT00728572 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Surface EMG
Description: Surface EMG only, no intervention
Study NCT00728572 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Logan Basic Technique Sham
Description: Participants will receive a sham Basic Technique treatment, not indicated by examination.
Study NCT03111771 — intervention group
Intervention type: PROCEDURE
Intervention: cervical surgery
Description: cervical surgery for Group K-
Study NCT03535389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Knee 4DCT
Description: Dynamic knee 4DCT
Study NCT03535389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Knee 4DCT
Description: Dynamic knee 4DCT
Study NCT01596738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~2. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization
Study NCT01596738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~2. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization
Study NCT01221389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Plasma
Description: Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
Study NCT03986411 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phase 1: Qualitative interviews: Health care professionals
Description: Semi-structured interviews of health care professionals to explore current management of urinary incontinence in the community
Study NCT03986411 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phase 2: Physiotherapy for urinary incontinence
Description: Tailored physiotherapy assessment and management for athletic women who self-report urinary incontinence
Study NCT03986411 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phase 3: Qualitative Interviews: Participants
Description: Semi-structured interviews of a purposeful selection of the participants from Phase 2 to explore reaction to the recruitment process and the intervention
Study NCT01066637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F](+/-)NOS
Description: Injection of radiotracer \[18F\](+/-)NOS for PET imaging and kinetic data analysis
Study NCT02022098 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
Study NCT04032717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-Griffithsin (Q-GRFT) enema
Description: Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
Study NCT00725244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar eletrocoagulation
Description: Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
Study NCT04032717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo enema
Description: Approximately 125mL of 0.9% sodium chloride solution
Study NCT02022098 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
Study NCT02022098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Debio 1143 solution
Study NCT02022098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution
Study NCT04334902 — intervention group
Intervention type: DEVICE
Intervention: mPDia
Description: Clinical decision support system for diagnosing neurodegenerative parkinsonism
Study NCT04182165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gili BioSensor System/ Gili Pro X BioSensor System
Description: Usability study
Study NCT00476502 — intervention group
Intervention type: GENETIC
Intervention: identify genetic polymorphism in Thai HIV infected
Description: Gene sequencing of Cyp450 metabolic pathway
Study NCT02485340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-ISMN (isosorbide-5-mononitrate)
Description: 5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT02485340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-ISMN (isosorbide-5-mononitrate)
Description: 5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT02485340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: 5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT02485340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT00725244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Plasma Coagulation
Description: Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort.
Study NCT01273506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 25-mg TRF
Description: 50 mg TRF single oral dose
Study NCT02402686 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
Study NCT03476616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone (-based therapy) arm
Description: At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
Study NCT03476616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan (-based therapy) arm
Description: At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
Study NCT04015869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopregnanolone
Description: neurosteroid
Study NCT04015869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo
Study NCT01852279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI-FES
Description: Brain computer Interface delivered Function Electrical Stimulation
Study NCT01852279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive muscle stimulation
Description: Functional Electrical stimulation delivered by therapist
Study NCT02474537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Single 200 mg dose INC280
Study NCT03874520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video triage
Description: The operator will offer the parent calling regarding the sick child to assess the child on video, as compared to the current standard; on the telephone.
Study NCT02181439 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: (LLLT Low Level Laser Therapy) SiroLaser advance
Description: Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
Study NCT01273506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 50-mg TRF
Description: 50 mg TRF single oral dose
Study NCT00642122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 0.5mg once daily
Study NCT01721421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extended treatment time
Description: patients receive extended dialysis treatment time time of 6 hours
Study NCT01721421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: extended treatment time
Description: patients receive extended dialysis treatment time time of 6 hours
Study NCT01721421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment time
Study NCT00642122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 1mg once daily
Study NCT00642122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 1mg twice daily
Study NCT00642122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 2mg once daily
Study NCT01721421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment time
Study NCT03282188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reolysin
Description: Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
Study NCT00642122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 4.00mcg twice daily
Study NCT00409149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM Approache
Study NCT00409149 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH approach
Description: standard dietary DASH approach in hypertensive patients
Study NCT02581852 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cross sectional assessment
Description: Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
Study NCT03282188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
Study NCT02145728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Functional Therapy
Description: Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
Study NCT02145728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Exercise Classes
Description: Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
Study NCT03043989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 6 infusions of Docetaxel with 18 doses clarithromycin